Headlines about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9786738060749 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of research firms have recently commented on FMI. BidaskClub cut shares of Foundation Medicine from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 26th. Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “hold” rating in a report on Wednesday, July 18th. Finally, William Blair lowered shares of Foundation Medicine from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 19th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $99.00.
Foundation Medicine stock opened at $137.00 on Friday. The stock has a market cap of $5.09 billion, a PE ratio of -30.44 and a beta of -0.10. The company has a debt-to-equity ratio of 4.76, a current ratio of 2.27 and a quick ratio of 1.98. Foundation Medicine has a one year low of $31.70 and a one year high of $137.20.
In related news, insider Michael J. Doherty sold 2,675 shares of the stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $136.66, for a total value of $365,565.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Roche Holdings Inc purchased 16,221,027 shares of the business’s stock in a transaction on Tuesday, July 31st. The stock was acquired at an average cost of $137.00 per share, with a total value of $2,222,280,699.00. The disclosure for this purchase can be found here. Insiders sold a total of 10,994 shares of company stock valued at $1,502,440 in the last quarter. 3.00% of the stock is currently owned by insiders.
About Foundation Medicine
Foundation Medicine, Inc provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.